ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0834

Heterogeneity in the Association of Genetic Risk for Rheumatoid Arthritis and Resultant Rheumatoid Arthritis Phenotypes
Abstract Number: 2661

Heterogeneity of RA-ILD by Longitudinal Forced Vital Capacity Measurements Is Associated with Survival and Respiratory Hospitalization
Abstract Number: 2034

Hidden Burden in Rheumatology: Cross-Sectional Study of Hearing Loss in Systemic Autoimmune Diseases
Abstract Number: 0383

Hidden Risk in Low Frailty: Impact of Elixhauser Comorbidities on In-Hospital Mortality Among Osteoporosis Patients — A Nationwide Analysis
Abstract Number: 0425

High Density Lipoprotein Dysfunction in Juvenile Idiopathic Arthritis as Compared to Children without Rheumatologic Disease
Abstract Number: 1056

High diagnostic rate of genetic testing in adult patients with autoinflammation: A Single Center Experience
Abstract Number: 1745

High Emotional Distress Predicts Suboptimal Cardiovascular Health Among Patients with Juvenile-Onset Lupus and Dermatomyositis: Longitudinal Analysis of the Lupus Erythematosus and Dermatomyositis Stress and Cardiovascular Health Cohort Study
Abstract Number: 2680

High Health Care Utilization Preceding Diagnosis of Juvenile Idiopathic Arthritis
Abstract Number: 2536

High Levels of Fatigue and Poor Sleep Quality in Behçet’s Disease: a Cross-sectional Study from a Non-endemic Area
Abstract Number: 1981

High Patient Satisfaction with a Medication Education Program: Program to Understand Rheumatology Medications with Pharmacist Led Education
Abstract Number: 1202

High Prevalence of Asymptomatic Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Validation of ACR/CHEST Risk Factors in a Hong Kong Cohort
Abstract Number: 2491

High Prevalence of Autoimmunity and Cancer in Anti-NOR90-positive Patients: A Multicenter Observational Study
Abstract Number: 1174

High Prevalence of Autoimmunity in Rosai Dorfman Disease: A Multinational Study
Abstract Number: 1504

High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) somatic mutations in a cohort of 1,073 SLE participants
Abstract Number: 0549

High Prevalence of Obstructive Sleep Apnea in Psoriatic Arthritis: A Polysomnography-Based Cross-Sectional Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].